title: Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues.
abstract: BACKGROUND
  To explore the expression of DcR3 protein and its clinicopathological significance in bladder urothelial carcinomas (BUC).
  
  
  METHODS
  Immunohistochemistry was performed to detect the expression of DcR3, caspase-3, Bcl-2, VEGF, Ki-67, PCNA and P53 in 166 BUC and 56 normal bladder tissues. Western blotting was used to detect the expression of DcR3 in the supernatants of cultured BUC cells.
  
  
  RESULTS
  Overexpression of DcR3 was found in BUC tissues and cell lines, with significant elevation as compared to normal bladder tissues (p<0.0001). Higher DcR3 expression was related to the status of invasion, lymph node metastasis and recurrence. Furthermore, DcR3 expression was negatively correlated with caspase-3 and positively associated with Bcl-2, VEGF, Ki-67 labeling index (LI), PCNA LI and P53 (all p<0.0001), respectively.
  
  
  CONCLUSIONS
  DcR3 may play a crucial role as an oncogene in tumorigenesis, deterioration and progress of BUC via influencing related pathways of apoptosis, proliferation and angiogenesis. The detection of DcR3 protein in the formalin- fixed and paraffin-embedded samples could assist to predict in prognosis of BUC patients.
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China E-mail : chen_gang_triones@163.com.
authors.forename: Yi-Qiang
authors.initials: YQ
authors.lastname: Jiang
authors.forename: Teng-Fei
authors.initials: TF
authors.lastname: Zhong
authors.forename: Yi-Wu
authors.initials: YW
authors.lastname: Dang
authors.forename: Ling-Song
authors.initials: LS
authors.lastname: Zou
authors.forename: Liu
authors.initials: L
authors.lastname: Yang
authors.forename: Xia
authors.initials: X
authors.lastname: Yang
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D053323:Receptors, Tumor Necrosis Factor, Member 6b / Q000378:metabolism*; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D019459:Urothelium / Q000378:metabolism / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor; D053323:Receptors, Tumor Necrosis Factor, Member 6b; C505911:TNFRSF6B protein, human